EMBER-3: East Asian Subgroup
December 10, 2025 • ESR1 Mutated ER HER2 Advanced Breast Cancer Content Hub
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients with ER+/HER2- advanced breast cancer, imlunestrant alone improved progression-free survival (PFS) over standard therapy in those with ESR1 mutations, and adding abemaciclib further enhanced PFS across all East Asian patients regardless of ESR1 status. The tolerability and safety profile observed in this subgroup was consistent with the overall trial population, supporting the regimen’s potential applicability in East Asian patients.
